EQR
60
-8
KEY
60
10
MET
51
-7
PG
40
-11
BF.B
43
-8
FRT
58
3
FMC
36
3
SYY
48
-2
ABBV
60
-8
PPL
45
-7
NEE
41
-3
KMI
51
-8
UAL
54
6
EQIX
57
7
MDLZ
40
4
SE
44
-5
PNW
48
-2
PRU
57
6
DUK
47
-15
ETR
49
-3
EQR
60
-8
KEY
60
10
MET
51
-7
PG
40
-11
BF.B
43
-8
FRT
58
3
FMC
36
3
SYY
48
-2
ABBV
60
-8
PPL
45
-7
NEE
41
-3
KMI
51
-8
UAL
54
6
EQIX
57
7
MDLZ
40
4
SE
44
-5
PNW
48
-2
PRU
57
6
DUK
47
-15
ETR
49
-3
Financhill
Back

Akero Therapeutics Quote, Financials, Valuation and Earnings

7 Stocks to Own Before the 2024 Election

Click the link below to get your copy. FREE
Buy
69

AKRO
Akero Therapeutics

Last Price:
22.40
Seasonality Move:
56.48%

7 Day Trial

ALL ACCESS PASS

$ 7

FREE Report: Could these High Yield Stocks wreck your retirement?

Get Your Copy of "20 High-Yield Dividend Stocks that Could Ruin Your Retirement" Here.

Akero Therapeutics Price Quote

$22.40
-0.76 (-3.28%)
(Updated: July 2, 2024 at 6:55 PM ET)

Akero Therapeutics Key Stats

Buy
69
Akero Therapeutics (AKRO) is a Buy
Day range:
$23.14 - $24.20
52-week range:
$11.25 - $53.77
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.89%
Volume:
672.4K
Avg. volume:
948.3K
1-year change:
-50.4%
Market cap:
$1.6B
Revenue:
$0
EPS:
$-3.23

How Much Does Akero Therapeutics Make?

Data Unavailable

Is Akero Therapeutics Growing As A Company?

Data Unavailable

Akero Therapeutics Stock Price Performance

What Is Akero Therapeutics 52-Week High & Low?

Akero Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akero Therapeutics?

Is Akero Therapeutics Cash Flow Positive?

  • What Is AKRO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$155.9M
  • What Is Akero Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $705.1M
  • What Is Akero Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$183.4M

Akero Therapeutics Return On Invested Capital

Data Unavailable

Akero Therapeutics Earnings Date & Stock Price

Akero Therapeutics Competitors

Akero Therapeutics Dividend Yield

Data Unavailable

Akero Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 2.83%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 44.56
Upside from Last Price: 92.38%

Major Shareholders

  • How many AKRO shares are owned by institutional investors?
    109.6M AKRO shares are owned by institutional investors
  • How many AKRO shares are owned by insiders?
    1.3M AKRO shares are owned by insiders